Compare Honeywell International Inc (HON) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs TransMedics Group Inc — how do they compare? Honeywell International Inc trades at $208.56 (market cap $65.48B), while TransMedics Group Inc trades at $79.31 (market cap $2.74B). The key difference: Honeywell International Inc is far larger — about 23.9× TransMedics Group Inc's market cap, and Honeywell International Inc pays a 1.36% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 90 Days and TransMedics Group Inc for 24 Days on average.
| HON | TMDX | |
|---|---|---|
Market Cap | $65.48B | $2.74B |
Volume | 2,047,782 | 949,331 |
Sector | Industrials | Health |
52-Week High | $248.79 | $150.42 |
52-Week Low | $188.14 | $61.99 |
Typical Hold Time | 90 Days | 24 Days |
Enterprise Value | $90.27B | $3.13B |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $208.11, down 2.24% on the day, with a bearish technical signal from moving averages but strong fundamentals including a low P/E of 7.94 and robust ROE of 47.43%. Recent earnings beats and a $300 million refinery project win highlight operational strength, while the company's post-spin focus on automation drives growth expectations.
The outlook is positive with a consensus price target of $259.25 implying 24.6% upside, supported by analyst bullishness (66.7% buy ratings). Risks include rising debt-to-asset ratios and cyclical exposure, but solid cash flow and dividend payments provide stability amid near-term volatility.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
